Overview
- Fabentech said it has received French market authorization to commercialize Ricimed for treating ricin poisoning.
- The company says the polyclonal antibody therapy targets and neutralizes ricin before it causes irreversible harm.
- More than €20 million in multi‑year agreements have been signed with several European countries for preventive stockpiling, according to the firm.
- This marks the first authorized ricin countermeasure in France and positions the product primarily for emergency reserves.
- Fabentech cites support from France’s defense authorities, the EU HERA program, and an early European Investment Bank loan, as ricin continues to be viewed as a bioterror risk.